The Health Ministry of the Russian Federation authorized phase I and II clinical trials of a recombinant vaccine for the prevention of cross-reactive birch pollen allergy to food, FMBA announced Thursday in a press briefing.

During the trials the effectiveness, safety, reactogenicity and inumunogenicity of the vaccine candidate will be evaluated in patients with allergic rhinitis and sensitivity to birch pollen, according to the agency.

Developed by FMBA’s Institute of Immunology, the new vaccine does not contain native allergen, unlike other drugs available on the market today.

Preclinical studies have shown that this vaccine, without peers in the world, provides a high degree of efficiency and safety. ef/abo/mem/gfa